Vaccines
Moderna and Merck’s mRNA Cancer Vaccine Succeeds in Landmark Phase 3 Melanoma Trial
The personalized vaccine plus Keytruda cut the risk of melanoma returning after surgery — the first positive Phase 3 result for an mRNA-based, individualized cancer vaccine.